{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05244798","nct_id":"NCT05244798","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05244798. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"sintilimab (D1 administration) was given in combination with chemotherapy (TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.","label":"Group of sintilimab combined with neoadjuvant chemotherapy","type":"EXPERIMENTAL"},{"description":"sintilimab (D1) was administered in combination with concurrent chemoradiotherapy. Chemotherapy regimen: TP regimen: albumin-paclitaxel + carboplatin, D1 administration, 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Radiotherapy regimen: according to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week. Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.","label":"Group of sintilimab combined with neoadjuvant chemoradiotherapy","type":"EXPERIMENTAL"},{"description":"The control group received neoadjuvant chemoradiotherapy and the regimen was as follows:Chemotherapy regimen: TP regimen: albumin paclitaxel + carboplatin, D1 administration, 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Radiotherapy regimen: according to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week. Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.","label":"Group of neoadjuvant chemoradiotherapy","type":"OTHER"}],"collaborators":["Peking University Cancer Hospital & Institute","Tianjin Medical University Cancer Institute and Hospital","Hebei Medical University Fourth Hospital","Anhui Provincial Hospital","The First Affiliated Hospital with Nanjing Medical University","Anyang Tumor Hospital","Shantou Central Hospital","Innovent Biologics (Suzhou) Co. Ltd.","GeneCast Biotechnology Co., Ltd."],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":{"count":420,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sintilimab","otherNames":[],"type":"DRUG"},{"name":"radiotherapy","otherNames":[],"type":"RADIATION"},{"name":"Chemotherapy","otherNames":[],"type":"DRUG"}],"last_update":"2022-10-25","lead_sponsor":"Sichuan Cancer Hospital and Research Institute","official_title":"Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy Plus Sintilimab Versus Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: a Multicenter, Randomized, Controlled, Phase III Trial","overall_status":"NOT_YET_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathology complete response rate, pCR","timeFrame":"3 months after the surgery"}],"references":[{"citation":"He W, Bai H, Lv J, Tang P, Hu T, Zhou H, Xiao W, Peng L, Liu G, Wang K, Fang Q, Qi Y, Liang L, Zheng X, Qing H, Chen Y, Zhou Y, Xie W, Han Y, Leng X. Neoadjuvant chemotherapy or chemoradiotherapy plus sintilimab versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a study protocol of a multicentre, randomised, controlled, phase III trial (SCIENCE study). BMJ Open. 2025 Jun 4;15(6):e095828. doi: 10.1136/bmjopen-2024-095828.","pmid":"40467307","type":"DERIVED"}],"start_date":{"date":"2022-11-01","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Sintilimab Plus NCT or NCRT Versus NCRT for ESCC","url":"https://clinicaltrials.gov/study/NCT05244798"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05244798"}